204 related articles for article (PubMed ID: 32143615)
1. Serum osteocalcin level is associated with the mortality in Chinese patients with Fibrodysplasia ossificans progressiva aged ≤18 years at diagnosis.
She D; Li R; Fang P; Zong G; Xue Y; Zhang K
BMC Musculoskelet Disord; 2020 Mar; 21(1):152. PubMed ID: 32143615
[TBL] [Abstract][Full Text] [Related]
2. Fibrodysplasia ossificans progressiva: clinical and genetic aspects.
Pignolo RJ; Shore EM; Kaplan FS
Orphanet J Rare Dis; 2011 Dec; 6():80. PubMed ID: 22133093
[TBL] [Abstract][Full Text] [Related]
3. Fibrodysplasia ossificans progressiva (FOP): watch the great toes!
Kartal-Kaess M; Shore EM; Xu M; Schwering L; Uhl M; Korinthenberg R; Niemeyer C; Kaplan FS; Lauten M
Eur J Pediatr; 2010 Nov; 169(11):1417-21. PubMed ID: 20577760
[TBL] [Abstract][Full Text] [Related]
4. The phenotype and genotype of fibrodysplasia ossificans progressiva in China: a report of 72 cases.
Zhang W; Zhang K; Song L; Pang J; Ma H; Shore EM; Kaplan FS; Wang P
Bone; 2013 Dec; 57(2):386-91. PubMed ID: 24051199
[TBL] [Abstract][Full Text] [Related]
5. Fibrodysplasia ossificans progressiva in China.
She D; Zhang K
Bone; 2018 Apr; 109():101-103. PubMed ID: 29175272
[TBL] [Abstract][Full Text] [Related]
6. Role of osteoclasts in heterotopic ossification enhanced by fibrodysplasia ossificans progressiva-related activin-like kinase 2 mutation in mice.
Kawao N; Yano M; Tamura Y; Okumoto K; Okada K; Kaji H
J Bone Miner Metab; 2016 Sep; 34(5):517-25. PubMed ID: 26204847
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of fibrodysplasia ossificans progressiva (FOP) in the United States: estimate from three treatment centers and a patient organization.
Pignolo RJ; Hsiao EC; Baujat G; Lapidus D; Sherman A; Kaplan FS
Orphanet J Rare Dis; 2021 Aug; 16(1):350. PubMed ID: 34353327
[TBL] [Abstract][Full Text] [Related]
8. Nonclassic fibrodysplasia ossificans progressiva: A child from Angola with an ACVR1
Martín-García D; Towler OW; Xu M; Alfonso-Hernández O; Oliveira PR; Alonso-Clavo M; Shore EM; Kaplan FS
Am J Med Genet A; 2021 Aug; 185(8):2572-2575. PubMed ID: 33973349
[TBL] [Abstract][Full Text] [Related]
9. Mutations of the noggin (NOG) and of the activin A type I receptor (ACVR1) genes in a series of twenty-seven French fibrodysplasia ossificans progressiva (FOP) patients.
Lucotte G; Houzet A; Hubans C; Lagarde JP; Lenoir G
Genet Couns; 2009; 20(1):53-62. PubMed ID: 19400542
[TBL] [Abstract][Full Text] [Related]
10. Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1(R206H) Fibrodysplasia Ossificans Progressiva (FOP) Mutation.
Chakkalakal SA; Uchibe K; Convente MR; Zhang D; Economides AN; Kaplan FS; Pacifici M; Iwamoto M; Shore EM
J Bone Miner Res; 2016 Sep; 31(9):1666-75. PubMed ID: 26896819
[TBL] [Abstract][Full Text] [Related]
11. Acute and chronic rapamycin use in patients with Fibrodysplasia Ossificans Progressiva: A report of two cases.
Kaplan FS; Zeitlin L; Dunn SP; Benor S; Hagin D; Al Mukaddam M; Pignolo RJ
Bone; 2018 Apr; 109():281-284. PubMed ID: 29241828
[TBL] [Abstract][Full Text] [Related]
12. Early mortality and cardiorespiratory failure in patients with fibrodysplasia ossificans progressiva.
Kaplan FS; Zasloff MA; Kitterman JA; Shore EM; Hong CC; Rocke DM
J Bone Joint Surg Am; 2010 Mar; 92(3):686-91. PubMed ID: 20194327
[TBL] [Abstract][Full Text] [Related]
13. Mutational screening of ACVR1 gene in Brazilian fibrodysplasia ossificans progressiva patients.
Carvalho DR; Navarro MM; Martins BJ; Coelho KE; Mello WD; Takata RI; Speck-Martins CE
Clin Genet; 2010 Feb; 77(2):171-6. PubMed ID: 19796185
[TBL] [Abstract][Full Text] [Related]
14. Fibrodysplasia ossificans progressiva: Review and research activities in Japan.
Haga N; Nakashima Y; Kitoh H; Kamizono J; Katagiri T; Saijo H; Tsukamoto S; Shinoda Y; Sawada R; Nakahara Y
Pediatr Int; 2020 Jan; 62(1):3-13. PubMed ID: 31774601
[TBL] [Abstract][Full Text] [Related]
15. A cumulative analogue joint involvement scale (CAJIS) for fibrodysplasia ossificans progressiva (FOP).
Kaplan FS; Al Mukaddam M; Pignolo RJ
Bone; 2017 Aug; 101():123-128. PubMed ID: 28465250
[TBL] [Abstract][Full Text] [Related]
16. Perhexiline maleate in the treatment of fibrodysplasia ossificans progressiva: an open-labeled clinical trial.
Kitoh H; Achiwa M; Kaneko H; Mishima K; Matsushita M; Kadono I; Horowitz JD; Sallustio BC; Ohno K; Ishiguro N
Orphanet J Rare Dis; 2013 Oct; 8():163. PubMed ID: 24131551
[TBL] [Abstract][Full Text] [Related]
17. Fibrodysplasia ossificans progressiva in Spain: epidemiological, clinical, and genetic aspects.
Morales-Piga A; Bachiller-Corral J; Trujillo-Tiebas MJ; Villaverde-Hueso A; Gamir-Gamir ML; Alonso-Ferreira V; Vázquez-Díaz M; Posada de la Paz M; Ayuso-García C
Bone; 2012 Oct; 51(4):748-55. PubMed ID: 22796417
[TBL] [Abstract][Full Text] [Related]
18. Heterotopic Ossification in Mouse Models of Fibrodysplasia Ossificans Progressiva.
Chakkalakal SA; Shore EM
Methods Mol Biol; 2019; 1891():247-255. PubMed ID: 30414138
[TBL] [Abstract][Full Text] [Related]
19. Fibrodysplasia ossificans progressiva: a current review of imaging findings.
Bauer AH; Bonham J; Gutierrez L; Hsiao EC; Motamedi D
Skeletal Radiol; 2018 Aug; 47(8):1043-1050. PubMed ID: 29445932
[TBL] [Abstract][Full Text] [Related]
20. Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an Acvr1
Convente MR; Chakkalakal SA; Yang E; Caron RJ; Zhang D; Kambayashi T; Kaplan FS; Shore EM
J Bone Miner Res; 2018 Feb; 33(2):269-282. PubMed ID: 28986986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
